Commencement of Share Buyback Programme

CVS Group plc

26 May 2026

 

For Immediate Release                                                                                                                                               26 May 2026

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Commencement of Share Buyback Programme

As separately announced today, CVS, the UK listed veterinary group and a leading provider of veterinary services, is launching a share buyback programme to purchase ordinary shares of 0.2 pence each ("Ordinary Shares") and has allocated up to £50 million to the buyback programme (the "Share Buyback Programme").

The purpose of the Share Buyback Programme is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Programme will be cancelled.

CVS has entered into agreements with each of Peel Hunt LLP ("Peel Hunt") and Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg") to purchase Ordinary Shares up to a maximum aggregate consideration (excluding expenses) of up to £50 million under the Share Buyback Programme. Peel Hunt and Berenberg will act as riskless principals and will make trading decisions concerning the timing of the purchases of Ordinary Shares independently of the Company.

The purchase of Ordinary Shares will be carried out on the London Stock Exchange and other trading venues. Any purchases of Ordinary Shares by the Company will be conducted in accordance with the general authority to purchase Ordinary Shares granted by its shareholders at the Company's Annual General Meeting on 18 November 2025, pursuant to which the maximum number of shares which remain available for purchase under the Share Buyback Programme is 6,040,012. The Share Buyback Programme will be conducted in accordance with Chapter 9 of the Financial Conduct Authority's Listing Rules and with European Union (EU) Regulation No 596/2014 ("MAR") and the MAR buyback technical standards (Commission Delegated Regulation (EU) 2016/1052) (the "Technical Standards"), both of which form part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018.

Any purchase of Shares pursuant to the Share Buyback Programme will be announced by no later than the end of the 7th daily market session following the calendar day on which such transaction occurred, as required by MAR.

The Share Buyback Programme is expected to be completed by 24 November 2026.

Contacts
CVS Group plc Richard Fairman, Chief Executive Officer Robin Alfonso, Chief Financial Officer Paul Higgs, Chief Veterinary Officer Charlotte Page, Head of Investor Relations	via FGS Global

FGS Global	[phone]
Faeth Birch Charlie Chichester	[e-mail]

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

END